Evicenter
MarkdownMedical informationP&T meetings
Rinzimetostat (ORIC-944)

Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide

Regulatory status
Not announced
Launch
Not announced
Last updated
165 sources

Section 4 of 6

Clinical evidence

121 evidence topics · 22 sources

Study summaries

Himalayas-1

Objective
Location and study date
Registry status and dates
Study characteristicQuoted record
Overall status“Recruiting”
Study start (actual)“2026-08-03”
Primary completion (estimated)“2028-03”
Study completion (estimated)“2030-09”
First posted“2026-07-23”
Study design
Eligibility criteria
Treatment
Investigational and control regimens
Study drug and armQuoted dose and schedule
Rinzimetostat (investigational arm)“400 mg once daily (QD)”
Darolutamide (investigational arm and physician's choice)“600 mg twice daily (BID)”
Enzalutamide (physician's choice)“160 mg once daily (QD)”
Docetaxel (physician's choice)“75 mg/m2 intravenously (IV) every 21 days for up to 10 cycles”
Study outcomes
Rationale for using radiographic progression-free survival by blinded independent central review as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition

No evidence found.

Baseline characteristics

No evidence found.

Efficacy results

No evidence found.

Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results

No evidence found.

Study limitations
Summary: design and data limitations
  • No Himalayas-1 results are available. The registry lists the trial as “Recruiting”, with an actual start of 2026-08-03 and estimated primary completion in 2028-03; the design information comes from the registry record, ORIC press releases and filings, and a trial-in-progress poster hosted on the ORIC website.
  • The trial is open label, with no masking (“None (Open Label)”). The primary endpoint, rPFS, is assessed by blinded independent central review per RECIST 1.1 for soft tissue and PCWG3 for bone.
  • The control is a prespecified physician’s choice of an ARPI or docetaxel. Participants assigned to the ARPI control undergo a second 1:1 randomization to darolutamide or enzalutamide, so darolutamide is given in the investigational arm and in part of the control arm; randomization is stratified by control category, prior docetaxel in mCSPC, and hepatic metastases.
  • Overall survival is a key secondary endpoint, formally tested only if the primary rPFS analysis is statistically significant. A consensus statement describes the association between rPFS and overall survival as “still being investigated”; a trial-level analysis of 143 randomized trials in advanced prostate cancer concluded that commonly used clinical end points “are not clear valid surrogate end points for OS”, while an analysis of 11 randomized trials supported rPFS as a valid intermediate endpoint in first-line ARPI-naive mCRPC, a population that differs from the post-abiraterone population of Himalayas-1.
  • Eligibility limits the population to participants with ECOG performance status 0 or 1 and adequate organ function, and excludes brain metastases, clinically significant cardiovascular disease, active inflammatory gastrointestinal disease, and prior treatment with ARPIs other than abiraterone, chemotherapy other than docetaxel for mCSPC, radioligand therapy, PARP monotherapy, or PRC2 inhibitors.
  • The 400 mg dose was selected from phase 1b dose-optimization data in 18 participants at 400 mg and 15 at 600 mg. ORIC conducts and sponsors the trial, and Bayer supplies darolutamide.

ORIC-944-01

Objective
Location and study date
Registry dates
FieldQuoted record
Study start (actual)“2022-06-01”
Primary completion (estimated)“2027-06”
Study completion (estimated)“2028-04”
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using recommended phase 2 dose as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Planned enrollment
FieldQuoted record
Enrollment (estimated)“275”
Darolutamide dose optimization, post-androgen receptor pathway inhibitor safety set: participants at the January 2026 cutoff
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Combination dose exploration: demographics and baseline characteristics at the September 2025 cutoff
CharacteristicRinzimetostat plus apalutamide or darolutamide (N=20)
Age, median (range), years“71 (48-85)”
Race, White / Black or African American / Asian, %“70 / 25 / 5”
ECOG performance status 0 / 1, n (%)“12 (60) / 8 (40)”
Gleason score <8 / ≥8, n (%)“4 (20) / 15 (75)”
Prior lines of therapy, median (range)“3 (2-5)”
Prior abiraterone, n (%)“20 (100)”
Prior docetaxel, n (%)“7 (35)”
Prior immune therapy, n (%)“7 (35)”
Prior PARP inhibitor, n (%)“2 (10)”
Prior radium 223, n (%)“2 (10)”
Prior other therapy, n (%)“6 (30)”
Bone metastases, n (%)“17 (85)”
Lymph node metastases, n (%)“8 (40)”
Visceral metastases, n (%)“3 (15)”
Darolutamide dose optimization, 400 mg and 600 mg post-abiraterone cohorts: demographics and baseline characteristics at the January 2026 cutoff
CharacteristicRinzimetostat 400 mg QD plus darolutamide (n=18)Rinzimetostat 600 mg QD plus darolutamide (n=15)
Age, median (range), years“67 (51, 85)”“77 (58, 91)”
Race, White / Black / Asian, %“56 / 33 / 6”“67 / 27 / 0”
ECOG performance status 0 / 1, %“56 / 44”“53 / 47”
Gleason score <8 / ≥8 / unknown, %“6 / 67 / 28”“33 / 40 / 27”
Baseline PSA, median, ng/mL“26”“12”
Prior lines of therapy, median (range)“2 (1-4)”“2 (1-4)”
Prior abiraterone, n (%)“18 (100)”“15 (100)”
Prior docetaxel, n (%)“7 (39)”“2 (13)”
Prior immune therapy, n (%)“3 (17)”“2 (13)”
Prior PARP inhibitor, n (%)“1 (6)”“3 (20)”
Prior radium 223, n (%)“3 (17)”“0”
Prior other therapy, n (%)“1 (6)”“0”
Bone metastases, n (%)“15 (83)”“12 (80)”
Lymph node metastases, n (%)“9 (50)”“4 (27)”
Lung metastases, n (%)“1 (6)”“3 (20)”
Efficacy results
Darolutamide dose optimization, 400 mg: landmark radiographic progression-free survival at the March 2026 cutoff
LandmarkRadiographic progression-free survival (median follow-up 4.9 months)
Month 3“3-Month 93%”
Month 4“4-Month 84%”
Month 5“5-Month 84%”
Darolutamide dose optimization, 600 mg: efficacy relative to 400 mg in the exposure-response analysis at the January 2026 cutoff
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Single-agent dose escalation: treatment-related adverse events in at least 10% of participants at the December 2024 cutoff
Preferred term900 mg (N=6), all grade, n (%)900 mg (N=6), grade 3, n (%)Total (N=25), all grade, n (%)Total (N=25), grade 3, n (%)
Diarrhea“2 (33)”“–”“10 (40)”“–”
Fatigue“3 (50)”“–”“8 (32)”“–”
Decreased appetite“1 (17)”“–”“8 (32)”“–”
Nausea“3 (50)”“–”“7 (28)”“–”
Anemia“2 (33)”“2 (33)”“5 (20)”“3 (12)”
Platelet count decreased“3 (50)”“2 (33)”“5 (20)”“2 (8)”
White blood cell count decreased“2 (33)”“1 (17)”“3 (12)”“1 (4)”
Blood creatinine increased“1 (17)”“–”“3 (12)”“–”
Dizziness“1 (17)”“–”“3 (12)”“–”
Vomiting“1 (17)”“–”“3 (12)”“–”
Combination dose exploration, 400 mg to 1,200 mg: treatment-emergent adverse events attributed to study treatment at the September 2025 cutoff
Preferred term400 mg (n=3), grade 1-2400 mg, grade 3600 mg (n=9), grade 1-2600 mg, grade 3800 mg (n=5), grade 1-2800 mg, grade 31,200 mg (n=3), grade 1-21,200 mg, grade 3Total (N=20), grade 1-2Total, grade 3
Diarrhea“1 (33%)”“–”“3 (33%)”“1 (11%)”“4 (80%)”“–”“3 (100%)”“–”“11 (55%)”“1 (5%)”
Fatigue“1 (33%)”“–”“4 (44%)”“–”“3 (60%)”“–”“1 (33%)”“–”“9 (45%)”“–”
Nausea“1 (33%)”“–”“3 (33%)”“–”“2 (40%)”“–”“1 (33%)”“–”“7 (35%)”“–”
Dysgeusia“1 (33%)”“–”“2 (22%)”“–”“1 (20%)”“–”“1 (33%)”“–”“5 (25%)”“–”
Vomiting“–”“–”“3 (33%)”“–”“1 (20%)”“–”“–”“–”“4 (20%)”“–”
Hypothyroidism“–”“–”“2 (22%)”“–”“1 (20%)”“–”“1 (33%)”“–”“4 (20%)”“–”
Constipation“–”“–”“2 (22%)”“–”“1 (20%)”“–”“–”“–”“3 (15%)”“–”
Blood creatinine increased“1 (33%)”“–”“–”“–”“1 (20%)”“–”“1 (33%)”“–”“3 (15%)”“–”
Darolutamide dose optimization, 600 mg post-abiraterone cohort: treatment-emergent adverse events attributed to study treatment at the January 2026 cutoff
Preferred termGrade 1, n (%)Grade 2, n (%)Grade 3, n (%)All grade, n (%)
Fatigue“4 (27)”“2 (13)”“–”“6 (40)”
Diarrhea“3 (20)”“2 (13)”“–”“5 (33)”
Nausea“2 (13)”“2 (13)”“–”“4 (27)”
Blood creatinine increased“2 (13)”“–”“–”“2 (13)”
Decreased appetite“–”“1 (7)”“–”“1 (7)”
Anemia“2 (13)”“–”“–”“2 (13)”
Darolutamide dose optimization, 400 mg post-androgen receptor pathway inhibitor safety set: treatment-emergent adverse events attributed to study treatment at the January 2026 cutoff
Preferred termGrade 1, n (%)Grade 2, n (%)Grade 3, n (%)All grade, n (%)
Fatigue“4 (11)”“6 (16)”“–”“10 (27)”
Diarrhea“6 (16)”“1 (3)”“–”“7 (19)”
Nausea“7 (19)”“–”“–”“7 (19)”
Blood creatinine increased“3 (8)”“2 (5)”“1 (3)”“6 (16)”
Decreased appetite“1 (3)”“4 (11)”“–”“5 (14)”
Anemia“3 (8)”“1 (3)”“–”“4 (11)”
Darolutamide dose optimization, 600 mg post-androgen receptor pathway inhibitor safety set: treatment-emergent adverse events attributed to study treatment at the January 2026 cutoff
Preferred termGrade 1, n (%)Grade 2, n (%)Grade 3, n (%)All grade, n (%)
Fatigue“5 (14)”“3 (9)”“–”“8 (23)”
Diarrhea“8 (23)”“5 (14)”“–”“13 (37)”
Nausea“5 (14)”“3 (9)”“–”“8 (23)”
Blood creatinine increased“5 (14)”“3 (9)”“–”“8 (23)”
Decreased appetite“4 (11)”“1 (3)”“–”“5 (14)”
Anemia“2 (6)”“3 (9)”“1 (3)”“6 (17)”
Darolutamide dose optimization, post-abiraterone cohorts (400 mg and 600 mg): dose modifications and discontinuations at the January 2026 cutoff
MeasureRinzimetostat 400 mg QD plus darolutamide (n=18)Rinzimetostat 600 mg QD plus darolutamide (n=15)
Dose interruptions“6%”“13%”
Dose reductions“None”“7%”
Treatment discontinuations“6%”“13%”
Darolutamide dose optimization, post-androgen receptor pathway inhibitor safety set (400 mg and 600 mg): dose modifications and discontinuations at the January 2026 cutoff
MeasureRinzimetostat 400 mg QD plus darolutamide (n=37)Rinzimetostat 600 mg QD plus darolutamide (n=35)
Dose interruptions“11%”“17%”
Dose reductions“3%”“9%”
Treatment discontinuations“3%”“11%”
Darolutamide dose optimization, 400 mg post-abiraterone cohort: grade 3 and serious treatment-related adverse events at the January 2026 cutoff
MeasureRinzimetostat 400 mg QD plus darolutamide (n=18)
Grade ≥3 treatment-related adverse events“6%”
Serious treatment-related adverse events“None”
Study limitations
Summary: design and data limitations
  • ORIC-944-01 is a first-in-human, open-label, multicenter phase 1/1b study with an interval 3+3 dose escalation design. Every cohort received rinzimetostat, alone or with an ARPI, and the study has no control arm. The primary endpoints of combination dose optimization are safety and the RP3D; rPFS, objective response rate, and duration of response are key secondary endpoints, and PSA and ctDNA are exploratory endpoints. The registry lists an estimated enrollment of 275 and an estimated primary completion in 2027-06.
  • Cohorts are small: 25 participants in single-agent dose escalation, 6 in the first apalutamide combination cohorts, 17 and then 20 in combination dose exploration, 18 at 400 mg and 15 at 600 mg in the post-abiraterone darolutamide dose-optimization cohorts, 19 in the post-androgen receptor inhibitor cohort, and 5 in the first food-effect report. The dose-exploration results pool participants who received apalutamide or darolutamide at 400 mg to 1,200 mg, and a footnote excludes three participants previously treated with lutetium 177, one of whom achieved a PSA50 response.
  • Follow-up is short: a median of 4.9 months in the 400 mg post-abiraterone cohort and 4.8 months in the post-androgen receptor inhibitor cohort. rPFS is reported as landmark rates; ORIC states that “Radiographic Progression-Free Survival Data Are Immature” and lists median rPFS as “Not mature”.
  • Endpoints of the 400 mg cohort come from different cutoffs and subsets: rPFS as of March 6, 2026 in 18 participants; PSA response at the January 16, 2026 clinical cutoff in 15 participants, excluding three without post-baseline PSA assessments; and ctDNA response in 14 participants (data on file as of March 11, 2026), excluding one without ctDNA at baseline and three without ctDNA data. Unconfirmed PSA responses are reported together with confirmed responses.
  • Baseline characteristics differed between the 400 mg and 600 mg post-abiraterone cohorts: median age 67 and 77 years, prior docetaxel 39% and 13%, and median baseline PSA 26 and 12 ng/mL. The exposure-response analysis used to select the RP3D pooled 113 participants from single-agent and combination cohorts.
  • All results are company-reported in press releases, investor presentations, and SEC filings. ORIC states that outcomes “may materially change as patient enrollment continues or more patient data become available”, that it may report unconfirmed responses and “interim analyses of only certain endpoints rather than all endpoints”, and that early clinical results “may not be predictive” of later-stage trials. ORIC’s comparisons with mevrometostat use competitor rPFS percentages “estimated from published data” and are labeled cross-trial.